General Information of Drug (ID: DM5FKU1)

Drug Name
CAR-T cells targeting Muc1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DM5FKU1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Mucin-1 (MUC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W Pancreatic cancer 2C10 Phase 3 [3]
TG-4010 DMWE3GB Bipolar disorder 6A60 Phase 2/3 [4]
ICO-25 DMC13BQ Breast cancer 2C60-2C65 Phase 2 [5]
MUC1-Poly-ICLC DML7N4B Colorectal cancer 2B91.Z Phase 2 [6]
AS-1402 DMMX1EJ Breast cancer 2C60-2C65 Phase 2 [7]
Emepepimut-S DMCLT2F Non-small-cell lung cancer 2C25.Y Phase 2 [8]
GO-203-2c DMLWKZ7 Acute myeloid leukaemia 2A60 Phase 2 [9]
SAR-566658 DMT4FI5 Triple negative breast cancer 2C60-2C65 Phase 2 [10]
Pankomab-GEX DMAZ460 Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
ImMucin DM09JOZ Multiple myeloma 2A83 Phase 1/2 [12]
Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W Pancreatic cancer 2C10 Phase 3 [3]
TG-4010 DMWE3GB Bipolar disorder 6A60 Phase 2/3 [4]
ICO-25 DMC13BQ Breast cancer 2C60-2C65 Phase 2 [5]
MUC1-Poly-ICLC DML7N4B Colorectal cancer 2B91.Z Phase 2 [6]
AS-1402 DMMX1EJ Breast cancer 2C60-2C65 Phase 2 [7]
Emepepimut-S DMCLT2F Non-small-cell lung cancer 2C25.Y Phase 2 [8]
GO-203-2c DMLWKZ7 Acute myeloid leukaemia 2A60 Phase 2 [9]
SAR-566658 DMT4FI5 Triple negative breast cancer 2C60-2C65 Phase 2 [10]
Pankomab-GEX DMAZ460 Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
ImMucin DM09JOZ Multiple myeloma 2A83 Phase 1/2 [12]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN CAR-T-Cell-Therapy [2]

References

1 ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
2 ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
3 Clinical pipeline report, company report or official report of Immunomedics.
4 A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
5 The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
6 Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
7 Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
8 Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
9 Clinical pipeline report, company report or official report of Genus Oncology.
10 Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
11 Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
12 Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.